ALVOTECH SA (ALVO:NASDAQ)
$5.78 0.11 (1.94%)
Analysed ALVOTECH SA (ALVO:NASDAQ) News Sources
Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations
31-08-2026
yahoo.com
Alvotech Shares Rise 5.6% After Barclays Upgrades Rating and Doubles Price Target
16-09-2026
advfn.com
ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside
16-09-2026
stocktwits.com
Why This Biotech Stock Just Got a Rare Double Upgrade
16-09-2026
yahoo.com
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
05-10-2026
yahoo.com
Alvotech stock surges after FDA manufacturing approval
05-10-2026
yahoo.com
Alvotech Soars 13% on FDA Nod That “Effectively Doubles” US Humira Biosimilar Capacity
05-10-2026
tikr.com
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
06-10-2026
yahoo.com
Alvotech (ALVO) Could Be 14% Undervalued On Manufacturing Capacity Updates
08-10-2026
yahoo.com
LOTTE Biologics and Alvotech announce US-based manufacturing agreement to increase global supply
08-10-2026
yahoo.com
What is the current price of ALVOTECH SA (ALVO:NASDAQ)?
The current price of ALVOTECH SA (ALVO:NASDAQ) is $5.78.
ALVOTECH SA (ALVO:NASDAQ) absolute price change since previous trading day?
The absolute price change of ALVOTECH SA (ALVO:NASDAQ) since the previous trading day is $0.11.
ALVOTECH SA (ALVO:NASDAQ) percentage price change since previous trading day?
The percentage price change of ALVOTECH SA (ALVO:NASDAQ) since the previous trading day is 1.94%.
What is the most recent average sentiment score for ALVOTECH SA (ALVO:NASDAQ)?
The most recent average sentiment score for ALVOTECH SA (ALVO:NASDAQ) is 82 out of 100.
What is the most recent average sentiment for ALVOTECH SA (ALVO:NASDAQ)?
The most recent sentiment for ALVOTECH SA (ALVO:NASDAQ) is .
SEC-8K** Filing Available For ALVOTECH SA (ALVO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.